Skip to main content
. 2020 Dec 23;5(1):1–11. doi: 10.1182/bloodadvances.2020003455

Figure 2.

Figure 2.

Cumulative incidence and 6-month survival in patients with and without TA-TMA. (A) Cumulative incidence of TA-TMA in all HSCT patients (N = 614). (B) Overall 6-month survival in allogeneic HSCT recipients with and without TA-TMA (n = 422). (C) Overall 6-month survival in autologous HSCT recipients with and without TMA (n = 192).